RBC Capital lowered the firm’s price target on Aptose Biosciences to $18 from $23 but keeps an Outperform rating on the shares. The company’s ESH data cut offers another layer of conviction in the tuspetinib/venetoclax combo’s potential as a salvage therapy in prior venetoclax failure patients, particularly in the FLT3-wt subset, the analyst tells investors in a research note. A stream of data catalysts ahead could drive new momentum for both the clinical and the investment case for Aptose, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on APTO:
- Aptose Biosciences reports Q3 EPS ($1.76), consensus ($2.05)
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- APTO Earnings this Week: How Will it Perform?
- Aptose Biosciences presents highlights from webcast on tuspetinib
- Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
